AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28434463 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal yoga
Number of subjects: 94
Study 28434463 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (control group)
Number of subjects: 94
Study 25779951 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine plus 2 Gy total body irradiation (TBI)
Number of subjects: 53
Study 25779951 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy TLI plus anti-thymocyte globulin (ATG)
Number of subjects: 53
Study 24113059 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 30
Study 24113059 — intervention group
Group type: COMPARATOR
Intervention: Topical formalin
Number of subjects: 30
Study 21982170 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia with oral midazolam premedication (0.5mg/kg 20‐30 minutes before induction)
Number of subjects: 167
Study 21982170 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with parental presence without premedication
Number of subjects: 167
Study 21982170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia with oral midazolam premedication
Number of subjects: 167
Study 21982170 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia with parental presence without premedication
Number of subjects: 167
Study 17678651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET)
Number of subjects: 166
Study 17678651 — intervention group
Group type: COMPARATOR
Intervention: No E(2) supplementation (control group)
Number of subjects: 166
Study 17678651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET) in long GnRH agonist suppression protocol
Number of subjects: 166
Study 17678651 — intervention group
Group type: COMPARATOR
Intervention: No E(2) supplementation (control group) in long GnRH agonist suppression protocol
Number of subjects: 166
Study 17678651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET) in GnRH antagonist or microdose GnRH agonist protocols
Number of subjects: 166
Study 17678651 — intervention group
Group type: COMPARATOR
Intervention: No E(2) supplementation (control group) in GnRH antagonist or microdose GnRH agonist protocols
Number of subjects: 166
Study 16533095 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week, one-on-one book-sharing intervention with twice-weekly 15-min sessions
Number of subjects: 30
Study 16533095 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 30
Study 14700441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical pimecrolimus cream
Number of subjects: 12
Study 14700441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11261480 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 0
Study 11261480 — intervention group
Group type: COMPARATOR
Intervention: Day 5 embryo transfer
Number of subjects: 0
Study 9168369 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-peptide enteral diet
Number of subjects: 50
Study 9168369 — intervention group
Group type: COMPARATOR
Intervention: Whole-protein diet
Number of subjects: 50
Study 7967299 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic trigonoplasty
Number of subjects: 12
Study 7967299 — intervention group
Group type: COMPARATOR
Intervention: Open trigonoplasty
Number of subjects: 12
Study 3121233 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and methotrexate
Number of subjects: 313
Study 3121233 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 313
Study 29766750 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 4881
Study 29766750 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4881
Study 27389963 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic periodontal therapy + 0.12% chlorhexidine
Number of subjects: 37
Study 27389963 — intervention group
Group type: COMPARATOR
Intervention: Basic periodontal therapy + placebo
Number of subjects: 37
Study 26050790 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise (n = 102)
Number of subjects: 204
Study 26050790 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 102)
Number of subjects: 204
Study 23040413 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine-enriched biscuits
Number of subjects: 15
Study 23040413 — intervention group
Group type: COMPARATOR
Intervention: Placebo biscuits
Number of subjects: 15
Study 23040413 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered L-arginine
Number of subjects: 15
Study 21569473 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 l/min of oxygen from a simple face mask
Number of subjects: 34
Study 21569473 — intervention group
Group type: COMPARATOR
Intervention: 4 l/min air from a face mask
Number of subjects: 34
Study 21569473 — intervention group
Group type: COMPARATOR
Intervention: Air from a fan
Number of subjects: 34
Study 21569473 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 34
Study 19351690 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-SR
Number of subjects: 22576
Study 19351690 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based strategies
Number of subjects: 22576
Study 19351690 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up PP as a continuous variable
Number of subjects: 22576
Study 19351690 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up SBP, DBP, MAP
Number of subjects: 22576
Study 16957557 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once/day
Number of subjects: 11
Study 16957557 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 400 mg once/day
Number of subjects: 11
Study 15002657 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluconolactone-containing products (PHAs)
Number of subjects: 0
Study 15002657 — intervention group
Group type: COMPARATOR
Intervention: Glycolic acid-containing products (AHAs)
Number of subjects: 0
Study 11110735 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once daily
Number of subjects: 199
Study 11110735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 199
Study 11110735 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Candesartan + Lisinopril)
Number of subjects: 199
Study 9066184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (1 to 2 mg/kg body weight, twice daily)
Number of subjects: 64
Study 9066184 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 64
Study 8332009 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 70
Study 8332009 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 70
Study 3089465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (maximum tolerable dose ranging from 10.6 to 37.1 mg)
Number of subjects: 6
Study 3089465 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 5 mg/kg
Number of subjects: 6
Study 3089465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 10 mg
Number of subjects: 6
Study 3089465 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 29722619 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (WBVT)
Number of subjects: 20
Study 29722619 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 26750674 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 47
Study 26750674 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine (NTG)
Number of subjects: 47
Study 25210909 — intervention group
Group type: EXPERIMENTAL
Intervention: FHP intervention (n=12 health centers)
Number of subjects: 918
Study 25210909 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC intervention (n=9 health centers)
Number of subjects: 918
Study 25210909 — intervention group
Group type: COMPARATOR
Intervention: HCC control group (n=11 health centers)
Number of subjects: 918
Study 25210909 — intervention group
Group type: EXPERIMENTAL
Intervention: FHP intervention
Number of subjects: 918
Study 22870960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 5.1J (60J/cm²) energy density, applied at three different points intraorally immediately and at 48 and 72 hours post-surgery
Number of subjects: 14
Study 22870960 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (laser device applied without activation)
Number of subjects: 14
Study 20046173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg) and Diazepam (0.1 mg/kg)
Number of subjects: 120
Study 20046173 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.05 mg/kg) and Fentanyl (1 microg/kg)
Number of subjects: 120
Study 18371114 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (THAL) arm of TT2
Number of subjects: 899
Study 18371114 — intervention group
Group type: COMPARATOR
Intervention: Total therapy 1 (TT1)
Number of subjects: 899
Study 18371114 — intervention group
Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2) without THAL
Number of subjects: 899
Study 18371114 — intervention group
Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2)
Number of subjects: 899
Study 18371114 — intervention group
Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2) without cytogenetic abnormalities (CA)
Number of subjects: 899
Study 18371114 — intervention group
Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2) with cytogenetic abnormalities (CA)
Number of subjects: 899
Study 16236670 — intervention group
Group type: EXPERIMENTAL
Intervention: National all farm index (AFI) ratio
Number of subjects: 2360
Study 16236670 — intervention group
Group type: COMPARATOR
Intervention: National fuel index
Number of subjects: 2360
Study 16236670 — intervention group
Group type: COMPARATOR
Intervention: Regional milk prices
Number of subjects: 2360
Study 12879828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritized review criteria for angina
Number of subjects: 81
Study 12879828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritized review criteria plus feedback for angina
Number of subjects: 81
Study 12879828 — intervention group
Group type: COMPARATOR
Intervention: Full guidelines for asthma
Number of subjects: 81
Study 12879828 — intervention group
Group type: COMPARATOR
Intervention: Reduced guidelines for asthma
Number of subjects: 81
Study 12879828 — intervention group
Group type: COMPARATOR
Intervention: Prioritized review criteria for asthma
Number of subjects: 81
Study 12879828 — intervention group
Group type: COMPARATOR
Intervention: Prioritized review criteria plus feedback for asthma
Number of subjects: 81
Study 10901965 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART) - 59.4 Gy in 33 fractions over 24 days
Number of subjects: 320
Study 10901965 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) - 70 Gy in 35 fractions over 49 days
Number of subjects: 320
Study 8666709 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed participants
Number of subjects: 0
Study 8666709 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 8227859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (0.5, 5, and 50 nmol)
Number of subjects: 16
Study 8227859 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallidin (0.5, 5, and 50 nmol)
Number of subjects: 16
Study 8227859 — intervention group
Group type: EXPERIMENTAL
Intervention: [desArg9]-bradykinin (50 nmol)
Number of subjects: 16
Study 8227859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 16
Study 8227859 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (antihistamine)
Number of subjects: 16
Study 3897335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 0
Study 3897335 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics
Number of subjects: 0
Study 30370830 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral and vaginal tenofovir formulations for HIV prevention
Number of subjects: 322
Study 27159248 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology (CIC) specimens from exposed nasal bulbar conjunctiva
Number of subjects: 22
Study 27159248 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology (CIC) specimens including fields without goblet cells
Number of subjects: 22
Study 24319038 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural motor cortex stimulation (MCS)
Number of subjects: 5
Study 24319038 — intervention group
Group type: COMPARATOR
Intervention: Control (off-stimulation)
Number of subjects: 5
Study 21613384 — intervention group
Group type: EXPERIMENTAL
Intervention: A1298/A1298 major allele homozygosity
Number of subjects: 2154
Study 21613384 — intervention group
Group type: EXPERIMENTAL
Intervention: A1298/A1298 homozygotes
Number of subjects: 2154
Study 21613384 — intervention group
Group type: EXPERIMENTAL
Intervention: C677T haplotype analysis
Number of subjects: 2154
Study 20642705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 3000
Study 18327092 — intervention group
Group type: EXPERIMENTAL
Intervention: 'in‐treatment' segmental wall motion abnormalities
Number of subjects: 749
Study 15796632 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 171
Study 15796632 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF)
Number of subjects: 171
Study 15796632 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (DTC)
Number of subjects: 171
Study 11910258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 284
Study 11910258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 284
Study 11910258 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 284
Study 11910258 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine, Sertraline, Paroxetine
Number of subjects: 284
Study 10485776 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 2.0% with 0% nitrous oxide
Number of subjects: 72
Study 10485776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2.5% with 33% nitrous oxide
Number of subjects: 72
Study 10485776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 3.0% with 66% nitrous oxide
Number of subjects: 72
Study 10485776 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 3.5% with 0% nitrous oxide
Number of subjects: 72
Study 8842861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting or purging (reported by 23% of participants, n = 205)
Number of subjects: 886
Study 8842861 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 886
Study 1908604 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 100 mg twice a day reducing to 50 mg twice a day over 48 hours
Number of subjects: 23
Study 1908604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6150839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg and 10 mg doses per 24 hours
Number of subjects: 10
Study 31550820 — intervention group
Group type: EXPERIMENTAL
Intervention: Real world study (RWS)
Number of subjects: 0
Study 31550820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Number of subjects: 0
Study 31550820 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic research
Number of subjects: 0
Study 31550820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic research
Number of subjects: 0
Study 31550820 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive research
Number of subjects: 0
Study 31550820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoeconomic data
Number of subjects: 0
Study 30413199 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing intrauterine contraceptive device (LNG IUD)
Number of subjects: 1860
Study 26415520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program (three individualized in-hospital education sessions and three weekly sessions of telephone counseling)
Number of subjects: 66
Study 26415520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program
Number of subjects: 66
Study 26415520 — intervention group
Group type: COMPARATOR
Intervention: Control group (supervised exercise and activities of daily living performance regimen, education)
Number of subjects: 66
Study 24823959 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame training (playing exergames on an unstable platform)
Number of subjects: 61
Study 24823959 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training (control)
Number of subjects: 61
Study 24823959 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task (ST) exercises on the unstable platform
Number of subjects: 61
Study 22741167 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular salad dressing as a dip
Number of subjects: 152
Study 22741167 — intervention group
Group type: EXPERIMENTAL
Intervention: Light (reduced energy/fat) dressing as a dip
Number of subjects: 152
Study 22741167 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed with regular dressing as a sauce
Number of subjects: 152
Study 22741167 — intervention group
Group type: COMPARATOR
Intervention: Plain (without dressing)
Number of subjects: 152
Study 22254048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (mixture of long‐chain fructo‐oligosaccharides, galacto‐oligosaccharides, and acidic oligosaccharides)
Number of subjects: 104
Study 22254048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation
Number of subjects: 104
Study 22254048 — intervention group
Group type: COMPARATOR
Intervention: Control (non-supplemented)
Number of subjects: 104
Study 18277519 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent stimuli in different modalities (national anthems, stories, architectural objects, paintings)
Number of subjects: 223
Study 18277519 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of thrills from music (Rachmaninoff and Haydn)
Number of subjects: 223
Study 18277519 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming stimuli
Number of subjects: 223
Study 18277519 — intervention group
Group type: COMPARATOR
Intervention: Altruism, self-concept, and mood measures
Number of subjects: 223
Study 16137275 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multidisciplinary geriatric intervention (n=155)
Number of subjects: 319
Study 16137275 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=164)
Number of subjects: 319
Study 12177585 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 453
Study 12177585 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (3-15 mg/day)
Number of subjects: 453
Study 9528165 — intervention group
Group type: EXPERIMENTAL
Intervention: D + O (Dextromethorphan + Oxatomide)
Number of subjects: 20
Study 9528165 — intervention group
Group type: COMPARATOR
Intervention: D (Dextromethorphan)
Number of subjects: 20
Study 7629335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (GIC) restorations
Number of subjects: 0
Study 7629335 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 0
Study 7629335 — intervention group
Group type: COMPARATOR
Intervention: Composite restorations
Number of subjects: 0
Study 2146863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF; 3 pmol/kg/min; 10 ng/kg/min)
Number of subjects: 12
Study 2146863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus hydrochlorothiazide (P+T)
Number of subjects: 450
Study 323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus hydrochlorothiazide plus hydralazine (P+T+H)
Number of subjects: 450
Study 323525 — intervention group
Group type: COMPARATOR
Intervention: Reserpine plus hydrochlorothiazide (R+T)
Number of subjects: 450
Study 323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus hydralazine (P+H)
Number of subjects: 450
Study 323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol alone (P)
Number of subjects: 450
Study 31549622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation (BSC) intervention delivered by mental health specialists trained to deliver evidence‐supported smoking cessation interventions
Number of subjects: 526
Study 31549622 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 526
Study 31549622 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC intervention
Number of subjects: 526
Study 28605159 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention
Number of subjects: 0
Study 26031313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed personalized feedback intervention regarding alcohol consumption
Number of subjects: 286
Study 26031313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 286
Study 23818227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrus OCT
Number of subjects: 42
Study 23818227 — intervention group
Group type: COMPARATOR
Intervention: GDx-VCC
Number of subjects: 42
Study 21805462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group (education and encouraged to obtain 10,000 steps per day)
Number of subjects: 106
Study 21805462 — intervention group
Group type: COMPARATOR
Intervention: Usual Lifestyle group (no change in activity advised)
Number of subjects: 106
Study 21805462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 20008235 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)
Number of subjects: 0
Study 20008235 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Number of subjects: 0
Study 20008235 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT (autologous stem cell transplantation)
Number of subjects: 0